In study after study, injected GLP-1 weight loss medications appear to work better on average for women than they do for men.

FRANKFURT, Germany (AP) — Pharmaceutical company Novo Nordisk A/S, maker of blockbuster weight loss drug Wegovy, said Friday ...

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...

Tirzepatide promoted greater weight loss in individuals with obesity than semaglutide in a clinical trial that compared the ...

It was the first head-to-head comparison of the injectable GLP-1 medications semaglutide and tirzepatide, which are sold under the brand names Wegovy and Zepbound for weight loss. Roughly 750 ...

Injectable GLP-1 receptor agonist drugs Wegovy (semaglutide) and Zepbound (tirzepatide ... first to undertake a head-to-head comparison of the weight loss effectiveness of semaglutide and ...

In the first head-to-head trial of its kind, people with obesity who took tirzepatide (sold under the brand names Mounjaro ...

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical ...